儿童肝母细胞瘤36例预后分析

发布时间：2018-01-31 01:43

  本文关键词： 肝母细胞瘤 治疗 预后 儿童　出处：《临床儿科杂志》2017年02期 　论文类型：期刊论文

【摘要】：目的探讨肝母细胞瘤(HB)患儿的预后。方法回顾性收集2010年9月至2015年2月初治HB患儿的病历及随访资料,总结临床疗效和预后。结果共纳入HB患儿36例,男23例、女13例,中位年龄20个月。36例患儿的中位随访时间37个月(7~71个月)。36例患儿死亡8例,参照美国儿童肿瘤研究组(POG/CCG)亚组分析,Ⅰ、Ⅱ期患儿预后明显好于Ⅲ、Ⅳ期,胎儿型患儿预后明显优于其他亚型(P0.05)。35例患儿疾病初期甲胎蛋白(AFP)水平增高,存活者治疗后AFP水平均降至正常;8例死亡患儿中3例复发后AFP水平增高,5例经辅助化疗AFP水平持续不降。初诊时乳酸脱氢酶(LDH)升高组(245 U/L)及C反应蛋白(CRP)升高组(5 mg/L)存活率明显低于正常组,天冬氨酸氨基转移酶(AST)≥80 U/L的患儿存活率明显低于AST80 U/L的患儿,差异均有统计学意义(P0.05)。结论血清AFP可作为HB复发和预后的监测指标。POG/CCG分期、病理分型是评估HB预后的重要因子,血清LDH、CRP、AST水平升高可能与HB患儿预后不良有关。
[Abstract]:Objective to investigate the prognosis of children with Hepatoblastoma (HBB). Methods the medical records and follow-up data of children with HB from September 2010 to early February 2015 were collected retrospectively. Results 36 children with HB were included, including 23 males and 13 females. The median follow-up time was 37 months, 7 ~ 71 months, and 36 cases died. According to the analysis of POG / CCG subgroup of American Children's Cancer Research Group, the median age was 20 months. The prognosis of stage 鈪，

本文编号：1477828